agn-241751
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 13, 2018 (NCT03586427)
Timeline
Indications
Studied for
Mechanism of action
- Glutamate NMDA receptorMODULATOR
Glutamate NMDA receptor modulator
- Glutamate receptor ionotropic, NMDA 2A (Grin2a) ↗
- Glutamate receptor ionotropic, NMDA 3B (Grin3b) ↗
- Glutamate receptor ionotropic, NMDA 2D (Grin2d) ↗
- Glutamate receptor ionotropic, NMDA 1 (Grin1) ↗
- Glutamate receptor ionotropic, NMDA 2B (Grin2b) ↗
- Glutamate receptor ionotropic, NMDA 2C (Grin2c) ↗
- Glutamate receptor ionotropic, NMDA3A (Grin3a) ↗
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03726658 | Phase 1/Phase 2 (Phase 2) | Nov 8, 2018 | Allergan |
| NCT03586427 | Phase 2 | Jun 13, 2018 | Allergan |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 2 | 2 | 1 | 2018 |
1 organizations
Page 1 / 1